CRVS - Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc.
863 Mitten Road
Suite 102
Burlingame, CA 94010
United States
650 900 4520
https://www.corvuspharma.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 29
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Dr. Richard A. Miller M.D. | Co-Founder, Pres, CEO & Chairman | 306k | N/A | 1951 |
| Dr. Peter A. Thompson FACP, M.D. | Co-Founder & Independent Director | 47k | N/A | 1960 |
| Mr. Leiv Lea | Chief Financial Officer | 388.73k | N/A | 1954 |
| Dr. William Benton Jones Ph.D. | Sr. VP of Pharmaceutical Devel. | 346.42k | N/A | 1966 |
| Dr. James T. Rosenbaum M.D. | Sr. VP of Research | N/A | N/A | N/A |
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
Corporate governance
Corvus Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.
